Voluntary announcement - ascletis' strategic partner sagimet announces first patient dosed in phase iii U.S. clinical trial of denifanstat (ASC40) for moderate to severe acne
Filed with HKEX · Stock code 1672 ·
6ix is reading this filing.
View original source (HKEXnews)Ascletis Pharma, Inc. on 6ix
Earlier from Ascletis Pharma
- Next Day Disclosure Return
- Voluntary announcement - ascletis announces positive preclinical data for the most comprehensive once-weekly oral peptide pipeline for the treatment of obesity
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Ascletis Pharma into a list and get an email when it puts out news.
Follow Ascletis Pharma